Treatment options in patients with systemic sclerosis-associated interstitial lung disease
Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedI...